CN110913853A - 具有使褪黑激素可溶于唾液的酸化剂的口腔溶解褪黑激素制剂 - Google Patents

具有使褪黑激素可溶于唾液的酸化剂的口腔溶解褪黑激素制剂 Download PDF

Info

Publication number
CN110913853A
CN110913853A CN201880041048.3A CN201880041048A CN110913853A CN 110913853 A CN110913853 A CN 110913853A CN 201880041048 A CN201880041048 A CN 201880041048A CN 110913853 A CN110913853 A CN 110913853A
Authority
CN
China
Prior art keywords
dosage form
saliva
composition
acid
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880041048.3A
Other languages
English (en)
Chinese (zh)
Inventor
赛义德·M·沙阿
丹尼尔·哈森
弗瑞德·哈森
帕特里克·科尔希诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Physicians Seal LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal LLC filed Critical Physicians Seal LLC
Publication of CN110913853A publication Critical patent/CN110913853A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880041048.3A 2017-06-20 2018-06-15 具有使褪黑激素可溶于唾液的酸化剂的口腔溶解褪黑激素制剂 Pending CN110913853A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
US62/522,473 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (1)

Publication Number Publication Date
CN110913853A true CN110913853A (zh) 2020-03-24

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880041048.3A Pending CN110913853A (zh) 2017-06-20 2018-06-15 具有使褪黑激素可溶于唾液的酸化剂的口腔溶解褪黑激素制剂

Country Status (13)

Country Link
US (4) US10500280B2 (cg-RX-API-DMAC10.html)
EP (1) EP3641759B1 (cg-RX-API-DMAC10.html)
JP (1) JP7297685B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200018652A (cg-RX-API-DMAC10.html)
CN (1) CN110913853A (cg-RX-API-DMAC10.html)
AU (1) AU2018289284A1 (cg-RX-API-DMAC10.html)
BR (2) BR122021012549B8 (cg-RX-API-DMAC10.html)
CA (1) CA3067822C (cg-RX-API-DMAC10.html)
ES (1) ES2979335T3 (cg-RX-API-DMAC10.html)
MX (1) MX2019015733A (cg-RX-API-DMAC10.html)
RU (1) RU2020101742A (cg-RX-API-DMAC10.html)
SG (1) SG11201912172YA (cg-RX-API-DMAC10.html)
WO (1) WO2018236678A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112426408A (zh) * 2020-12-08 2021-03-02 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US20240189331A1 (en) * 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
EP4351525A1 (en) * 2021-06-09 2024-04-17 AGB-Pharma AB Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120195968A1 (en) * 2011-01-28 2012-08-02 Shah Syed M Controlled-release melatonin compositions and related methods
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
WO2016141069A1 (en) * 2015-03-02 2016-09-09 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
US20110092602A1 (en) * 2008-04-25 2011-04-21 Nitin Shivcharan Laddha Rapidly disintegrating oral compositions of tramadol
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) * 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120195968A1 (en) * 2011-01-28 2012-08-02 Shah Syed M Controlled-release melatonin compositions and related methods
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
WO2016141069A1 (en) * 2015-03-02 2016-09-09 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. MUÑOZ等: "Obtaining fast dissolving disintegrating tablets with different doses of melatonin", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112426408A (zh) * 2020-12-08 2021-03-02 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺

Also Published As

Publication number Publication date
WO2018236678A1 (en) 2018-12-27
US20200268886A1 (en) 2020-08-27
KR20200018652A (ko) 2020-02-19
US11224658B2 (en) 2022-01-18
RU2020101742A (ru) 2021-07-20
AU2018289284A1 (en) 2020-01-16
US20180360967A1 (en) 2018-12-20
SG11201912172YA (en) 2020-01-30
US10960075B2 (en) 2021-03-30
US11224657B2 (en) 2022-01-18
US20200069803A1 (en) 2020-03-05
US20200268887A1 (en) 2020-08-27
BR122021012549B1 (pt) 2022-02-22
ES2979335T3 (es) 2024-09-25
BR122021012549B8 (pt) 2022-10-25
JP7297685B2 (ja) 2023-06-26
CA3067822A1 (en) 2018-12-27
BR112019027286A2 (pt) 2020-07-21
EP3641759B1 (en) 2024-04-03
BR112019027286B1 (pt) 2022-02-22
US10500280B2 (en) 2019-12-10
EP3641759A4 (en) 2021-03-24
JP2020524162A (ja) 2020-08-13
CA3067822C (en) 2022-08-30
MX2019015733A (es) 2020-02-20
EP3641759A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
US11224658B2 (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10493068B2 (en) Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat
EP4076380B1 (en) Transmucosal therapeutic system containing agomelatine
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
US11648240B2 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin
HK40019696A (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
Rajpurohit et al. An overview: Formulation aspects for mouth dissolving films
HK40110942A (en) Transmucosal therapeutic system containing agomelatine
HK40090941A (en) Transmucosal therapeutic system containing agomelatine
CN107296798A (zh) 抗发红组合物
HK40082929A (en) Transmucosal therapeutic system containing agomelatine
HK40082929B (en) Transmucosal therapeutic system containing agomelatine
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
HK40082930A (en) Transmucosal therapeutic system containing agomelatine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019696

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210624

Address after: Vevey

Applicant after: Societe des Produits Nestle S.A.

Address before: Boca Raton, Florida, USA

Applicant before: PHYSICIAN'S SEAL, LLC

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200324